Advanced search
Publication Cover
Biomarkers in Medicine Volume 13, 2019 - Issue 7
Submit an article Journal homepage
740
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Biomarkers of Venous Thromboembolism in Cancer: A Silent Echo From Local Events?

Emelie Gezelius1 Department of Clinical Sciences, Lund University, Skåne University Hospital, Oncology, Barngatan 4, SE-221 85, Lund, SwedenView further author information
&
Mattias Belting1 Department of Clinical Sciences, Lund University, Skåne University Hospital, Oncology, Barngatan 4, SE-221 85, Lund, Sweden;2 Department of Immunology, Pathology, & Genetics, Uppsala University, Rudbecklaboratoriet, SE-751 85, Uppsala, SwedenCorrespondence[email protected]
View further author information
Pages 507-509 | Received 29 Mar 2019, Accepted 02 Apr 2019, Published online: 29 May 2019

References

  • Trousseau A . Phlegmasia alba dolens. Clin. Mèd. de l'Hôtel-Dieu de Paris3, 654–712 (1865).
  • Blom JW , OsantoS, RosendaalFR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J. Thromb. Haemost.2(10), 1760–1765 (2004).
  • Sorensen HT , MellemkjaerL, OlsenJH, BaronJA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med.343(25), 1846–1850 (2000).
  • Belting M , AhamedJ, RufW. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler. Thromb. Vasc. Biol.25(8), 1545–1550 (2005).
  • Noble S . Heparins and cancer survival: where do we stand?Thromb. Res.133(Suppl. 2), S133–S138 (2014).
  • Belting M . Glycosaminoglycans in cancer treatment. Thromb. Res.133(Suppl. 2), S95–S101 (2014).
  • Zacharski LR , HendersonWG, RicklesFRet al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer53(10), 2046–2052 (1984).
  • Lebeau B , ChastangC, BrechotJMet al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer74(1), 38–45 (1994).
  • Altinbas M , CoskunHS, ErOet al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemostas.2(8), 1266–1271 (2004).
  • Zhang J , ZhangYL, MaKX, QuJM. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax68(5), 442–450 (2013).
  • Ek L , GezeliusE, BergmanBet al. Randomized Phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann. Oncol.29(2), 398–404 (2018).
  • Macbeth F , NobleS, EvansJet al. Randomized Phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J. Clin. Oncol.34(5), 488–494 (2016).
  • Meyer G , BesseB, DoubreHet al. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a Phase III clinical trial. Eur. Respir. J.52(4), 1–10 (2018).
  • Gezelius E , FlouKristensen A, BendahlPOet al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN – a randomized trial with low molecular weight heparin. PloS ONE13(11), e0207387 (2018).
  • Svensson KJ , KucharzewskaP, ChristiansonHCet al. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc. Natl Acad. Sci. USA108(32), 13147–13152 (2011).
  • Ay C , DunklerD, SimanekRet al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J. Clin. Oncol.29(15), 2099–2103 (2011).
  • Khorana AA , FrancisCW, MenziesKEet al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J. Thromb. Haemos.6(11), 1983–1985 (2008).
  • Manly DA , WangJ, GloverSLet al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb. Res.125(6), 511–512 (2010).
  • Pelzer U , OpitzB, DeutschinoffGet al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J. Clin. Oncol.33(18), 2028–2034 (2015).
  • Theunissen JW , CaiAG, BhattiMMet al. Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting. Mol. Cancer Ther.17(11), 2412–2426 (2018).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.